SCOTUS to hear biosimilar clash between Amgen and Sandoz
25-04-2017
AVNphotolab / iStockphoto.com
The US Supreme Court heard oral arguments from Amgen and Sandoz yesterday in the ongoing battle over a biosimilar version of Amgen’s Neupogen (filgrastim).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
SCOTUS, Amgen, Sandoz, BPCIA, patent, biosimilar, biologics, FDA, Federal Circuit
